PDF
ePub
Citation
Print
Abstract
Background and Objectives
The controversy over the optimal extent of thyroidectomy for papillary thyroid carcinoma (PTC) has persisted over a long time period. Particularly, there is a lack of consensus in low-risk PTC sized >1 cm and ≤2 cm. In this retrospective study, we analyzed the oncologic outcomes between hemi-thyroidectomy and total thyroidectomy in patients with low-risk PTC sized 2 cm or less.
Materials and Methods
A retrospective chart review of 1107 patients who were diagnosed as unilateral low-risk PTC with maximal tumor size 2 cm or less and initially underwent either hemi-thyroidectomy (n=550) or total thyroidectomy (n=557) was conducted. All patients underwent ipsilateral prophylactic central neck dissection. Patients had no evidence of gross extrathyroidal extension or lymph node metastasis. Clinicopathologic factors and recurrence rate were compared according to the surgical extent and factors correlated to recurrence were analyzed.
Results
While the total thyroidectomy group had more aggressive clinicopathologic factors such as minimal extrathyroidal extension, multifocality, and lymph node metastasis, recurrence rate was higher in the hemi-thyroidectomy group (p=0.006). However, when the contralateral lobe recurrence was excluded there was no difference in recurrence between the two groups (p=0.597). In patients with tumor sized >1 cm and ≤2 cm there was no significant difference in recurrence between the two groups (p=0.100).
Figures and Tables
Fig. 1
Recurrence free survival for papillary thyroid carcinoma according to the size of the tumor and the extent of thyroidectomy. (A) 2 cm or less. (B) 1 cm or less. (C) >1 cm and ≤2 cm. (D) Outside of contralateral lobe.
References
1. Yi KH, Lee EK, Kang HC, Koh Y, Kim SW, Kim IJ, et al. 2016 Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 2016; 9(2):59–126.
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26(1):1–133.
3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220–241.
4. Park S, Oh CM, Cho H, Lee JY, Jung KW, Jun JK, et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ. 2016; 355:i5745.
5. Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015; 4(1):52–62.
6. Kebebew E, Clark OH. Differentiated thyroid cancer: “complete” rational approach. World J Surg. 2000; 24(8):942–951.
7. Lee J, Park JH, Lee CR, Chung WY, Park CS. Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid. 2013; 23(11):1408–1415.
8. Ito Y, Kudo T, Kihara M, Takamura Y, Kobayashi K, Miya A, et al. Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J. 2012; 59(2):119–125.
9. Zhang TT, Li CF, Wen SS, Huang DZ, Sun GH, Zhu YX, et al. Effects of tumor size on prognosis in differentiated thyroid carcinoma smaller than 2 cm. Oncol Lett. 2019; 17(5):4229–4236.
10. Choi WR, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, et al. Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. Oral Oncol. 2019; 94:106–110.
11. Kim KM, Park JB, Bae KS, Kim CB, Kang DR, Kang SJ. Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. Endocr J. 2013; 60(3):291–297.
12. Zhu J, Wang X, Zhang X, Li P, Hou H. Clinicopathological features of recurrent papillary thyroid cancer. Diagn Pathol. 2015; 10:96.
13. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014; 260(4):601–605. discussion 5-7.
14. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010; 136(11):1055–1061.
15. Kuba S, Yamanouchi K, Hayashida N, Maeda S, Adachi T, Sakimura C, et al. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study. Int J Surg. 2017; 38:143–148.
16. Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery. 2017; 161(2):485–492.
17. Macedo FI, Mittal VK. Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: a meta-analysis. Surg Oncol. 2015; 24(2):117–122.
18. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007; 246(3):375–381. discussion 81-4.
19. Park JH, Yoon JH. Lobectomy in patients with differentiated thyroid cancer: indications and follow-up. Endocr Relat Cancer. 2019; 26(7):ERC-19-0085.R1.
20. Mishra A, Mishra SK. Total thyroidectomy for differentiated thyroid cancer: primary compared with completion thyroidectomy. Eur J Surg. 2002; 168(5):283–287.
21. James BC, Timsina L, Graham R, Angelos P, Haggstrom DA. Changes in total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer during the past 15 years. Surgery. 2019; 166(1):41–47.
XML Download